2005
DOI: 10.1016/j.amjmed.2005.01.029
|View full text |Cite
|
Sign up to set email alerts
|

Infliximab therapy in established rheumatoid arthritis: An observational study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
34
0
2

Year Published

2008
2008
2023
2023

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 52 publications
(38 citation statements)
references
References 22 publications
2
34
0
2
Order By: Relevance
“…In observational studies, continuation rates are usually lower than in clinical randomized trials, 66% of the patients continued infliximab infusions after one year [8] and after two years' intervention 67% [9] and 73% [10] drug survival rates were reported. In the study of Buch et al, only 27 out of 174 patients (16%) continued infliximab treatment at the 24 months' time-point [14].…”
Section: Other Adverse Eventsmentioning
confidence: 99%
See 2 more Smart Citations
“…In observational studies, continuation rates are usually lower than in clinical randomized trials, 66% of the patients continued infliximab infusions after one year [8] and after two years' intervention 67% [9] and 73% [10] drug survival rates were reported. In the study of Buch et al, only 27 out of 174 patients (16%) continued infliximab treatment at the 24 months' time-point [14].…”
Section: Other Adverse Eventsmentioning
confidence: 99%
“…Buch et al reported also that some patients could not maintain an already achieved response at later time points [14]. In observational studies, the rate of discontinuation due to inefficacy varies between 9.2-11% [8, 10,16]. In clinical studies, discontinuation rates due to inefficacy are around 10 % [1,2].…”
Section: Other Adverse Eventsmentioning
confidence: 99%
See 1 more Smart Citation
“…Patients receiving infliximab are more likely to discontinue therapy because of side effects, which are occasionally severe, as well as infections and infusion reactions [8] . However, infliximab has been found to have a relatively acceptable toxicity profile [3] . Characteristics of infliximab that may influence patient persistence include a preferred administration method and less frequent needle sticks compared with subcutaneous agents [13] .…”
Section: The Properties Of Three Anti-tnf-α Agentsmentioning
confidence: 99%
“…Anti-TNF-α therapy leads to substantial functional improvement in the vast majority of patients and down-regulates inflammatory cytokines stimulated by TNF-α. The use of methotrexate (MTX) in combination with three such agents has dramatically improved the treatment of severe RA [2][3][4][5][6] . Studies have established that combination therapy can provide greater therapeutic benefits than single-drug regimens.…”
Section: Introductionmentioning
confidence: 99%